Clinical Trial Update: Cylexin for Reduction of Reperfusion Injury in Infant Heart Surgery [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 clinical trial of Cylexin for reducing reperfusion injury during infant heart surgery has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Heart Defects

Drugs mentioned

• Cylexin

Snippet

Sponsor: Boston Children's Hospital | Conditions: Congenital Heart Defects | Phase 2, Phase 3 | Status: COMPLETED